A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Publisher： Karger

E-ISSN： 1423-0232|88|6|353-359

ISSN： 0030-2414

Source： Oncology, Vol.88, Iss.6, 2015-0, pp. : 353-359

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer

By  

Oncology, Vol. 85, Iss. 6, 2013-11 ,pp. : 317-322

Karger

Access to resources Recommend Favorite

Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study

By  

Oncology, Vol. 83, Iss. 3, 2012-08 ,pp. : 151-157

Karger

Access to resources Recommend Favorite

Phase II Trial of Cetuximab plus Irinotecan for Oxaliplatin- and Irinotecan-Based Chemotherapy-Refractory Patients with Advanced and/or Metastatic Colorectal Cancer: Evaluation of Efficacy and Safety Based on KRAS Mutation Status (T-CORE0801)

By  

Oncology, Vol. 87, Iss. 1, 2014-06 ,pp. : 7-20

Karger

Access to resources Recommend Favorite

A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study)

By  

Oncology, Vol. 91, Iss. 1, 2016-05 ,pp. : 24-30

Karger

Access to resources Recommend Favorite

Phase I/II Study of Twenty-Four-Hour Infusion of Irinotecan in Combination with Oral UFT plus Leucovorin for Metastatic Colorectal Cancer

By  

Oncology, Vol. 76, Iss. 5, 2009-03 ,pp. : 338-341

Karger

Access to resources Recommend Favorite